Bone marrow transplantation, 2016; doi:10.1038/bmt.2016.123. Authors: Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G, Budde L E, Pagel J M, Frayo S L, Roden J E, Hedin L, Press O W, Gopal A K et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; City of Hope National Medical Center, Duarte, CA, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; ...
Hotels near Fred Hutchinson Cancer Research Center, Seattle on TripAdvisor: Find 111,494 traveller reviews, 50,608 candid photos, and prices for 276 hotels near Fred Hutchinson Cancer Research Center in Seattle, WA.
One of the worlds leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow - not circulating, peripheral blood, which is the current norm - should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells - while the immune cells are still inside the body.. In a proof-of-principle study to be published April 17 [2017] in Nature Nanotechnology, the team showed that nanoparticle-programmed immune cells, known as T cells, can rapidly clear or slow the progression of leukemia in a mouse model.. "Our technology is the first that we know of to quickly program tumor-recognizing capabilities into T cells without extracting them for laboratory manipulation," said Fred Hutchs Dr. Matthias Stephan, the studys senior author. "The reprogrammed cells begin to work within 24 to 48 hours and continue to produce these receptors for weeks. This suggests that our technology has the potential to allow the immune system to quickly mount a strong enough response to destroy cancerous cells before the disease becomes ...
The Avgousti lab at the Fred Hutchinson Cancer Research Center has an opening for a postdoctoral fellow. Our laboratory uses a multidisciplinary approach to investigate the mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential. Our goal is to advance basic understanding of viral manipulation of chromatin and uncover new aspects of chromatin biology.. Much like the cellular genome, viral genomes are compacted in virus particles with small basic molecules to maximize space and be poised for gene expression. Some DNA viruses use cellular histone proteins to compact their genomes whereas others use small basic molecules. Adenoviruses encode their own histone-like protein, called protein VII, that forms a beads on a string assembly with the viral genome. By examining protein VII in host chromatin, we discovered that protein VII ...
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It
Market your lab products and lab equipment to the life science professionals at the Fred Hutchinson Cancer Research Center in Seattle, WA in the upcoming BioResearch Product Faire™ Event.
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs ...
Hill, GR, Ferrara, JL. "The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation". Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. "1994 Consensus Conference on Acute GVHD Grading". Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. "Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study". Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. "Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
Bone marrow transplantation, or allogeneic hematopoietic stem cell transplant (HCT), is the only curative therapy for many patients with leukemia. Certain immune cells, called T cells, contained in the donor HCT graft can cause a "graft versus leukemia" (GVL) effect which eliminates leukemic cells. Unfortunately, there are also donor T cells in the HCT graft that can cause a condition called "graft versus host disease" (GVHD). GVHD is a life-threatening immune response that remains the major barrier to the success of transplantation. Dr. ...
Burroughs LM, ODonnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG et al.. 2008. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(11):1279-87. Abstract ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
平成23年4月 岡山大学病院講師(輸血部). 【一言】丁寧で安定感のある診療を心がけています。. 【研究テーマ】移植後肺合併症、ドナーリンパ球輸注によるGVL効果. 【主な業績】. ● Nishie M , Fujii N, Mimura Y , Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M. Vigorous inflammatory responses in non-infectious pulmonary complication induced by donor lymphocyte infusion. Transfusion. 2015 (in press). ● Asano T, Fujii N, Niiya D, Nishimori H, Fujii K, Matsuoka K, Ichimura K, Hamada T, Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M. Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. Springerplus. 2014 Jan 2;3:3. ● Fujii N, Nakase K, Asakura S, Matsuo K, Nawa Y, Sunami K, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, Hara M, Tanimoto M ...
HOPA supports pharmacy practitioners and seeks to promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer
Graft-versus-host disease remains a major cause of transplant-related mortality. Interleukin-2 plus sirolimus synergistically reduces acute graft-versus-host disease in rodents and promotes regulatory T-cells. This phase II trial tested the hypothesis that interleukin-2 would facilitate STAT5 phosphorylation in donor T-cells, expand regulatory T-cells, and ameliorate graft-versus-host disease. Between 4/16/2014-12/19/2015, 20 patients received interleukin-2 (200,000IU/m2 thrice weekly, days 0 to +90) with sirolimus (5-14ng/ml) and tacrolimus (3-7ng/ml) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation. The study was designed to capture an increase in regulatory T-cells from 16.0% to ,23.2% at day +30. Interleukin-2/sirolimus/tacrolimus significantly increased regulatory T-cells at day +30 compared to our published data with sirolimus/tacrolimus (23.8% versus 16.0%, P=0.0016; 0.052 k/ul versus 0.037 k/ul, P=0.0163), achieving the primary study endpoint. However, ...
H.Joachim Deeg from Fred Hutchinson Cancer Research CenterClinical ResearchFull Member is a speaker at Eurocancersummit-2015 conference | Conferenceseries Ltd
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma. T2 - A CIBMTR analysis. AU - Epperla, Narendranath. AU - Ahn, Kwang W.. AU - Litovich, Carlos. AU - Ahmed, Sairah. AU - Battiwalla, Minoo. AU - Cohen, Jonathon B.. AU - Dahi, Parastoo. AU - Farhadfar, Nosha. AU - Farooq, Umar. AU - Freytes, Cesar O.. AU - Ghosh, Nilanjan. AU - Haverkos, Bradley. AU - Herrera, Alex. AU - Hertzberg, Mark. AU - Hildebrandt, Gerhard. AU - Inwards, David. AU - Kharfan-Dabaja, Mohamed A.. AU - Khimani, Farhad. AU - Lazarus, Hillard. AU - Lazaryan, Aleksandr. AU - Lekakis, Lazaros. AU - Murthy, Hemant. AU - Nathan, Sunita. AU - Nishihori, Taiga. AU - Pawarode, Attaphol. AU - Prestidge, Tim. AU - Ramakrishnan, Praveen. AU - Rezvani, Andrew R.. AU - Romee, Rizwan. AU - Shah, Nirav N.. AU - Sureda, Ana. AU - Fenske, Timothy S.. AU - Hamadani, Mehdi. PY - 2019/1/10. Y1 - ...
Fred Hutchs Business Development and Industry Relations manages and commercializes our intellectual property assets. Partners are vital to the commercialization process; our goal is to work as efficiently and collaboratively as possible to achieve shared goals.
Blood, 1996; 88 (9) doi:. Authors: Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E, Furlong T, Hansen J A, Gooley T, Maher R M, Martin P, McSweeney P A, Sullivan K M, Anasetti C, Fay J W et al.(9) Affiliation: Fred Hutchinson Cancer Research Center, United States Sample size: 25 Abstract: The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. ...
Non-competitive 5K and one mile run/walk in support of research and awareness for multiple myeloma the second most common type of blood cancer.
Bioinformatics community open to all people. Strong emphasis on open access to biological information as well as Free and Open Source software.
Womens Health Initiative, Fred Hutchinson Cancer Research Center, PO Box 19024, Mail Stop M3-A410, Seattle, WA 98109, USA. [email protected] ‎(1) ...
Cancer Focus: Leukemia , MDS, Multiple Myeloma-Plasma Cell Tumor , Myelodysplastic Syndromes (MDS) Dr. Claudio Anasetti is a senior member and chair of the Department of Blood and Marrow Transplant at Moffitt Cancer Center. He also directs Moffitts blood and marrow transplant fellowship program and is a professor of oncology at the University of South Florida. Dr. Anasettis research interests include the prevention and treatment of graft-versus-host disease, blood and bone marrow transplantation and immunogenetics and donor selection. Dr. Anasetti graduated cum laude from the University of Perugia School of Medicine in Italy, where he also served a residency in internal medicine. He completed a fellowship in immunology at Childrens Memorial Hospital in Oklahoma City and an oncology fellowship at the University of Washington - Fred Hutchinson Cancer Research Center in Seattle, WA. Before coming to Moffitt in 2004, Dr. Anasetti was a member of the faculty at Fred Hutchinson Cancer Research ...
allogeneic HCT to a previously unserved population of older or medically infirm patients. Use of this regimen also has contributed to improving allogeneic HCT outcomes over the past decade. Herein, we describe outcomes among 372 patients aged 60 years or older with advanced hematologic malignancies who underwent allogeneic HCT in prospective clinical trials. Between March 4, 1998, and December 24, 2008, 372 patients aged 60 to 75 years underwent allogeneic HCT for advanced hematologic malignancies after nonmyeloablative conditioning per multi institutional protocols executed at 18 centers coordinated through the Fred Hutchinson Cancer Research Center, Seattle, Washington.. The primary differences between protocols were the addition of fludarabine to 2 Gy total body irradiation, the SNX-5422 use of HLA matched related or unrelated or HLA mismatched grafts, variations in the duration and intensity of posttransplantation immunosuppressive medications, and disease specific protocols. These changes ...
BACKGROUND AND OBJECTIVES: Leukemia relapse occurring in donor cells after allogeneic hematopoietic stem cell transplantation has been reported in rare cases. Cytogenetic analysis and molecular probing of variable number of tandem repeats (VNTRs) have been used to confirm this unusual event in the few cases so far reported in the literature. The aim of this study was to demonstrate that extensive molecular characterization of leukemic cells at diagnosis and relapse may be necessary to avoid many technical pitfalls possibly leading to an erroneous diagnosis of leukemia relapse in donor cells after allogeneic transplantation. DESIGN AND METHODS: We report the case of a 49- year old man who received an allogeneic transplantation from his HLA-identical sister because of BCR-ABL+ acute lymphoblastic leukemia (ALL). After having achieved complete hematologic and molecular remission, two years later an overt leukemia relapse occurred with cytogenetic findings suggesting a leukemia relapse in donor ...
Liu Hong-tao,Liu Dai-hong,Huang Xiao-jun,et al. Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion[J]. CHINESE MEDICAL JOURNAL,2013,126(22):4380-4388 ...
TY - JOUR. T1 - Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation. AU - van der Heiden, P. L. J.. AU - Arbous, M. S.. AU - van Beers, E. J.. AU - van den Bergh, W. M.. AU - le Cessie, S.. AU - Demandt, A. M. P.. AU - Eefting, M.. AU - Hess, C.. AU - Kusadasi, N.. AU - Marijt, W. A. F.. AU - van Mook, W. N. K. A.. AU - Müller, M. C. A.. AU - Tuinman, P. R.. AU - van Vliet, M.. AU - van Westerloo, D. J.. AU - Blijlevens, N. M. A.. AU - Biemond, Bart J.. AU - Vlaar, Alexander J.. AU - Spoelstra, Angelique M.. AU - Hilkens, Murielle. AU - Kluin, Hanneke C.. AU - on behalf of the HEMA-ICU Study Group. PY - 2019/3/1. Y1 - 2019/3/1. N2 - Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to ...
The progress that has been made in the treatment of SLL/CLL has resulted from the development of new anti-cancer therapies, the use of autologous and allogeneic stem cell transplants, and the performance of clinical trials. Future progress will result from continued participation in appropriate clinical trials. Currently, there are several areas of active exploration aimed at improving the treatment of SLL/CLL with allogeneic stem cell transplantation.. Use of Peripheral Blood Stem Cells: Stem cells may be collected from a number of sites in the body, including the bone marrow and the peripheral blood. Physicians at The Fred Hutchinson Cancer Center, City of Hope, and Stanford University performed a randomized clinical trial comparing allogeneic bone marrow transplantation (BMT) to peripheral blood stem cell (PBSC) transplantation in patients with leukemia and lymphoma. The results of this study were presented at the American Society of Hematology Annual Meeting in New Orleans.. Patients ...
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) offers curative potential to a number of older patients with acute myeloid leukemia (AML) in their first complete remission. However, there are limited data in the literature concerning post-HCT outcomes for older patients in their second complete remission (CR2). METHODS: The purpose of the current study was to retrospectively investigate within the Center for International Blood and Marrow Transplant Research database parameters influencing posttransplant outcomes for patients 60 years of age or older undergoing HCT for AML in CR2. RESULTS: In total, 196 patients from 78 centers were identified; the median age was 64 years (range, 60-78 years). Seventy-one percent had a Karnofsky performance status ≥ 90 at the time of HCT. Reduced-intensity conditioning regimens were used in 159 patients (81%). A univariate analysis demonstrated a 3-year overall survival (OS) rate of 42% (95% confidence interval [CI], 35%-49%), a leukemia-free ...
allogeneic stem cell transplant is the only potential cure for chronic myelogenous leukemia (cml). the procedure is usually done if youre young and dont have any medical issues besides cml.
This trial will investigate the efficacy and tolerability of temsirolimus [Torisel] + stem cell transplant in patients with advanced, metastatic and tyrosine
BACKGROUND: Notwithstanding 1 documented case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several subsequent cases of allo-SCT in HIV-1 positive individuals have failed to cure HIV-1 infection. The aim of our study was to describe changes in the HIV reservoir in a single chronically HIV-infected patient on suppressive antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia. METHODS AND FINDINGS: We prospectively collected peripheral blood mononuclear cells (PBMCs) by leukapheresis from a 55-year-old man with chronic HIV infection before and after allo-SCT to measure the size of the HIV-1 reservoir and characterize viral phylogeny and phenotypic changes in immune cells ...
Conventionally, the gold standard for acceptance of solid organ transplantation has been through pharmacological application of immunosuppressive agents. Although such agents have been remarkably successful for short-term allograft survival, long-term survival has been elusive. The downside to long-term application of immunosuppressive drugs is increased risk for infections [1], malignancy [2], and ultimately chronic rejection of the organ graft [3,4]. Thus, it has long been the goal of transplantation biologists to develop alternative methods that render the patients immune system specifically tolerant towards the allograft without requiring life-long administration of immunosuppressive drugs. Immunological tolerance through hematopoietic cell transplantation (HCT) has proven to be an effective solution to this problem both in preclinical animal models and the clinic [5,6].. The concept of immune tolerance was first developed in the mid-1940s when Ray Owen published on the observation that ...
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.
ContextA minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematolo
The Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Childrens Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.
The landscape of transplantation in MDS has evolved rapidly in the last decade, driven mostly by advances in patient selection through better risk stratification, increasing age of allogeneic recipients, introduction of reduced intensity conditioning (RIC) regimens, increased availability of unrelated donors, new donor sources and improvements in transplant technology and supportive care. Despite these advances, several issues, mostly centering on approaches to improve posttransplant survival while minimizing transplant related mortality continue to
Understanding the role of specific Treg populations for the prevention of GVHD is of increasing importance given that Treg therapy is now in the early stages of implementation in BM transplant recipients. In initial studies, unselected CD4+ CD25+ T cells have been administered to allogeneic BMT recipients with the ultimate goal that this approach will attenuate GVHD severity (37, 38). To date, whereas cells have been able to be administered safely, it is not clear how potent they are in abrogating GVHD severity. Moreover, whether this is the optimal Treg population and to what extent various Treg subpopulations cooperate to maintain immune tolerance are undefined (39). It is against this backdrop that we examined whether other Treg populations might be important in the regulation of GVHD. The studies described in this work now define CD8+ Foxp3+ T cells as another Treg population that plays a role in the maintenance of transplantation tolerance in allogeneic stem cell transplant ...
造血幹細胞移植時のウイルス感染症監視体制と治療の現状 Monitoring of CMV infection and CMV specific T lymphocytes following allogeneic stem cell transplantation ...
Research study reports extending survival in mice by 70 percent; initial studies in humans are under way. Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.. In a paper to be published in the March 20 issue of Cancer Cell, senior author Sunil Hingorani, M.D., Ph.D., an associate member of the Hutchinson Centers Clinical Research and Public Health Sciences divisions, and colleagues describe the biological mechanisms of how the tumor barrier is formed and detail a newly discovered way to break it down. Their research significantly increased the length of survival in a genetically engineered mouse model of the ...
Allotransplants (allo- from the Greek meaning "other") is the transplantation of cells, tissues, or organs, to a recipient from a genetically non-identical donor of the same species.[1] The transplant is called an allograft, allogeneic transplant, or homograft. Most human tissue and organ transplants are allografts. A xenograft is a graft from a different species, such as when animal tissue is grafted into human tissue, or when human cancer cells are implanted in mice for experimental tumor studies. Allografts can be referred to as "homostatic" if they are biologically inert when transplanted, such as bone and cartilage.[2]. An immune response against an allograft or xenograft is termed rejection. An allogenic bone marrow transplant can result in an immune attack, called Graft-versus-host disease.. ...
Synonyms for allogeneic graft in Free Thesaurus. Antonyms for allogeneic graft. 47 synonyms for graft: transplant, implant, shoot, bud, implant, sprout, splice, scion, labour, work, industry, effort, struggle, sweat, toil, slog, exertion. What are synonyms for allogeneic graft?
September 1, 2014.. Dr. Ulrich is currently serving as a Director of the National Center for Tumor Diseases and Department Head at the German Cancer Research Center in Heidelberg, Germany. She will assume a leadership role at Huntsman Cancer Institute, serving as Senior Director of Population Sciences. Her husband, Bruce A. Edgar, PhD, currently a Professor and Researcher at the German Cancer Research Center-Center for Molecular Biology Heidelberg Alliance, will head a laboratory at Huntsman Cancer Institute. Both researchers have previously held faculty positions at the Fred Hutchinson Cancer Research Center in Seattle, Washington.. "Dr. Ulrich and Dr. Edgar are a dynamic duo, bringing with them an incredible breadth of knowledge and experience from the cancer research world. They are highly regarded researchers, both in the United States and in Europe, and we are indeed fortunate to have them join our ranks," said Mary Beckerle, PhD, CEO and Director of the Huntsman Cancer Institute.. Dr. ...
Transplantation with blood stem cells from donors for patients with Myelodysplastic Syndromes (MDS) has been introduced into clinical practice about 35 years ago. Initially, this innovative and revolutionary treatment has been pioneered in young and fit patients with advanced stages of MDS. Many patients died prematurely due to complications of the transplantation procedure despite the young age of patients and relapse rates were high due to the advanced stages in most patients. Nevertheless, it became more and more clear that a rewarding minority of the transplanted patients became long term survivors. We learned quite a lot from our experience during the early exploratory phase.. In the beginning, only matched family members could be used as a donor which implicated that a donor was only available in about 30% of the transplantation candidates. We could extend the number of available donors with unrelated donors thanks to better tissue typing techniques and the creation of large ...
Researchers at the Fred Hutchinson Cancer Research Center conducted a population-based, case-control study to consider whether the brassieres worn daily by millions of women might be linked to the disease that kills about 40,000 in the U.S. each year. What they found was a resounding no, no matter how many ways they looked at bra-use data from more than 1,000 Seattle-area women diagnosed with invasive breast cancer between 2000 and 2004. "Our study found no evidence that wearing a bra increases a womans risk for breast cancer," said Lu Chen, a researcher in the Public Health Sciences Division at Fred Hutch. "The risk was similar no matter how many hours per day women wore a bra, whether they wore a bra with underwire, or at what age they began wearing a bra." The researchers conducted in-person interviews to determine the bra-wearing habits of 1,044 women aged 55 to 74 diagnosed with the two most common types of breast cancer, invasive ductal carcinoma, or IDC, and invasive lobular carcinoma, ...
Seattle-based Nohla Therapeutics, a biotech startup spun out of the Fred Hutchinson Cancer Research Center, just announced a whopping $43.5 million Series A round, bringing the startups total funding to date to just under $65 million. The round was led by Arch Venture Partners and included 5AM…
Scientists at Fred Hutchinson Cancer Research Center have developed a new method for analyzing the Major Histocompatibility Complex (MHC) of the human genome. This large region, found on chromosome 6, encodes more than 400 known genes. The best known of these genes are the HLA genes that govern tissue type and participate in the immune system by protecting people from infection or by governing susceptibility to autoimmune diseases or cancer. The method may have the potential of being an efficient way to map genes in the MHC that are responsible for many human diseases, and might also be useful in studying other gene complexes that have a lot of variability ...
Manipulating proliferative, persistent T-cell subsets produces durable antitumor responses. Although adoptive T-cell therapies have yet to be approved by the FDA, this area of cancer immunotherapy is gaining ground "at a torrid pace," says Stanley Riddell, MD, of the Fred Hutchinson Cancer Research Center in Seattle, WA. Riddell shared his research teams progress in synthesizing and evaluating chimeric antigen receptor (CAR) T cells at the annual meeting of the American Association for the Advancement of Science in February.. CAR T-cell therapy involves inserting a synthetic receptor in patients T cells, which then recognize and destroy tumors expressing a specific antigen. So far, researchers have had remarkable success-albeit in small clinical trials-directing this therapy against CD19, which is expressed on the surface of all B cells, including B-cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Riddell reported a complete remission rate of 93% in 29 ...